Daniel David Gretler, MD
Dr. Gretler is Board Certified in Internal Medicine and Clinical Pharmacology and has worked in drug development for almost 30 years with the last 10 spent as a consultant in clinical pharmacology and early drug development. He received his MD from the University of Bern in his native Switzerland and his graduate medical training in Internal Medicine, Critical Care and Clinical Pharmacology at the University of Southern California and The University of Chicago, where his last position was Assistant Professor in the Committee on Clinical Pharmacology, Section of Cardiology. He started his drug development career at Syntex and held various positions there and later at COR Therapeutics, Millennium Therapeutics and Portola Pharmaceuticals. His last full-time position was Chief Medical Officer at Portola Pharmaceuticals. He has been Adjunct Clinical Associate Professor of Medicine at Stanford University for over 20 years. He has contributed to the development and approval of a number of drugs including CAMZYOS, NULIBRY, OXBRYTA, ANDEXXA, BEVIXXA (betrixaban), INTEGRILIN, CELLCEPT.
Learn more about Daniel